Adjuvant conversion to sirolimus in liver transplant patients with recurrent hepatocellular carcinoma - Preliminary results [4]

Transplant International

Volumn 21, Issue 1, 2008, Pages 96-99

  Kornberg, A ^a   Kupper B ^a   Tannapfel, A ^b   Thrum, K ^a   Wilberg, J ^a   Barthel E ^a   Settmacher, U ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN;

ANTINEOPLASTIC ACTIVITY; CLINICAL ARTICLE; FOLLOW UP; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; HUMAN TISSUE; LETTER; LIVER CELL CARCINOMA; LIVER GRAFT; LIVER TRANSPLANTATION; LOADING DRUG DOSE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT CANCER; TUMOR RECURRENCE; TUMOR VOLUME;

CARCINOMA, HEPATOCELLULAR; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM RECURRENCE, LOCAL; SIROLIMUS; TREATMENT OUTCOME;

EID: 36649018333     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2007.00567.x     Document Type: Letter

References (15)

1. Mazzafero V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996 334 : 693.
2. Schwarz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2004 127 : 268.
3. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001 33 : 1394.
4. Lubienski A. Hepatocellular carcinoma: interventional bridging to liver transplantation. Transplantation 2005 80 : 113.
5. Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma. Ann Surg 2004 240 : 451.
6. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002 35 : 519.
7. Roayaie S, Schwartz JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004 10 : 534.
8. Regalia E, Fassati LR, Valente U, et al. Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat Surg 1998 5 : 29.
9. Trotter JF. Sirolimus in liver transplantation. Transplant Proc 2003 35 : 193.
10. Elsharkawi M, Staib L, Henne-Bruns D, Mayer J. Complete remission of posttransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation 2005 79 : 855.
11. Ceriello A, Mezza F, Cozzolino S, et al. Role of immunosuppression in recurrence after liver transplantation for diethylnitrosamine-induced tumors in rats. Transpl Int 1994 7 (Suppl. 1 204.
12. Eckstein LA, Van Quill KR, Bui SK, Uusitalo MS, O'Brien JM. Cyclosporin a inhibits calcineurin/nuclear factor of activated T-cells signaling and induces apoptosis in retinoblastoma cells. Invest Ophthalmol Vis Sci 2005 46 : 782.
13. Schumacher G, Oidtmann M, Rueggeberg A, et al. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol 2005 11 : 1420.
14. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004 10 : 8421.
15. Kneteman NM, Oberholzer J, Al Saghier M, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004 10 : 1301.